volume 29 number 5 mAY 2011 nature biotechnology microvessels, which, after one year, are three times more likely to persist than vessels grown in Matrigel containing FGF2 alone. The vessels formed in the presence of FGF9 are more vasoreactive and able to regulate blood flow in response to agents such as phenylephrine and nitroprusside. These results point to the importance of supporting the survival, growth and recruitment of both endothelial cells and mural cells to make microvessels that persist long term.
Interestingly, there is a marketed product for wound healing that relies on PDGF (Regranex) 7 . Although study of this drug's mechanism of action has focused on proliferation and matrix production by mesenchymal cells, the present report 1 raises the possibility that part of PDGF's action in chronic wound healing may be due to enhancement of microvascular maturation. Indeed, when Pickering and colleagues 1 inject purified FGF9 into ischemic mouse hindlimb muscles, the resulting microvessels are more mature and invested with more smooth muscle cells than those generated in the absence of FGF9. In addition, FGF9 injection leads to accelerated regrowth of muscle mass, along with improved limb function, compared with vehicle.
Could FGF9 be used in patients to treat tissue ischemia due to microvascular disease? Pickering and colleagues 1 have shown the efficacy of intramuscular injection of FGF9 in promoting long-term microvessel formation in ischemic mice. Rodent results do not necessarily predict outcomes in humans, but it is certainly tempting to contemplate a 'cocktail' of endothelial-specific and smooth muscle-specific growth factors for clinical use. Such a cocktail might be delivered alone as a drug or in combination with autologous bone marrow-derived cells. The latter approach could enhance the efficacy of cell therapy with mononuclear cell fractions, which have recently shown some promise in clinical trials for limb ischemia 8 .
As we learn more about the dynamics of microvessel formation, it is becoming clear that there will be no 'magic bullet' for producing robust microvessels. Most likely, a combination of cell and growthfactor therapies will be needed to regenerate microvasculature at a level that can ease the symptoms of limb or myocardial ischemia. By identifying a potential new growth factor in this process, the work of Pickering and colleagues 1 brings us one important step closer to a truly effective treatment for microvascular disease. 4 . HMGB1 binds CD24, a membrane glycoprotein on dendritic cells, which in turn is bound by the inhibitory receptor SiglecG (for mouse) or SIGLEC10 (for human) on the surface of the same cell ( Fig. 1) . This ternary complex (HMGB1/CD24/Siglec) inhibits TLR signaling induced by HMGB1 (ref. 4) . The authors' new finding 2 that mice deficient in either SiglecG or CD24 exhibit dramatically increased mortality and production of inflammatory cytokines confirms the importance of this inhibitory circuit in sepsis.
COMPETING FINANCIAL INTERESTS
Siglecs are members of the immunoglobulin superfamily that recognize sialic acidcontaining glycans as ligands, an interaction that helps the immune system to distinguish self and non-self [5] [6] [7] . Of the 14 human Siglecs identified to date, 12 are primarily expressed on the majority of white blood cell types that constitute the immune system 5 . Most Siglecs, like SiglecG/10, are inhibitory co-receptors that suppress cell activation by means of tyrosine motifs in their cytoplasmic tail, dampening signaling from activating receptors 4, 5, 8, 9 .
SiglecG/10 is expressed primarily on B cells and has been implicated in making B cells toler ant to self antigens 5, 7, 8 , but it is also expressed on macrophages and dendritic cells 2,4 . Chen et al. 2 provide evidence that the antiinflammatory circuit mediated by SiglecG on dendritic cells involves recognition of sialylated glycans on CD24 (Fig. 1) . To investigate the role of dendritic cells, Chen et al. 2 generated a transgenic mouse expressing CD24 under a dendritic cell-specific promoter. Relative to CD24 null mice, the transgenic mice expressing CD24 only in dendritic cells produced lower levels of cytokines and exhibited reduced mortality in the intestinal sepsis model. Exactly how the inhibitory signal created by DAMP engagement of CD24/SiglecG Sepsis, a major cause of mortality for hospitalized patients 1 , arises from a massive overreaction of the immune system to bacterial pathogens, leading to widespread edema and harm to vital tissues. In this issue, Chen et al. 2 identify one piece of the mechanistic puzzle underlying sepsis and use this finding to develop a new therapeutic strategy. Working with a model of intestinal sepsis, they show that the inflammatory response is exacerbated by bacterial sialidases, which disrupt an inhibitory circuit in dendritic cells that keeps immune responses in check when 'self ' cells are damaged. Simply blocking sialidase activity with small-molecule inhibitors leads to a substantial reduction of the inflammatory response and subsequent morbidity.
Although the sequelae of sepsis and septic shock are complex, research has focused largely on understanding the roles of bacterial virulence factors. Bacterial molecules known as pathogen-associated molecular patterns (PAMPs) directly trigger inflammatory responses by activating Toll-like receptors (TLRs) 3 . A hallmark of TLR activation is the production of inflammatory cytokines, such as IL-6 and TNF, which act locally but are released systemically, producing a cascade of inflammatory responses that damage tissues. But TLRs are also activated by factors from damaged host cells. These 'self ' inflammatory triggers, called danger-associated molecular patterns (DAMPs), contribute substantially to the magnitude of the inflammatory insult and the severity of septic disease 3 .
The new findings of Chen et al. 2 concern this second, DAMP-mediated inflammatory pathway. In previous work, these authors demonstrated the existence of an inhibitory
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Sepsis can be ameliorated by small-molecule inhibitors of bacterial sialidases.
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suppresses DAMP-mediated signaling from TLRs remains uncertain.
The importance of this inhibitory circuit in intestinal sepsis suggested the possibility that bacterial sialidases may exacerbate inflammation in wild-type mice by cleaving sialic acids on CD24 that are required for recognition by SiglecG/10 ( Fig. 1) . Indeed, bacterial sialidases in the blood of mice after intestinal puncture reduced sialic acid levels on the surfaces of dendritic cells. In vitro, sialidase treatment of wild-type dendritic cells amplified cytokine production in response to HMGB1 but had no effect on the elevated levels of cytokines produced by dendritic cells from CD24 or SiglecG null mice. Moreover, sepsis induced by administration of the sialidase-producing Streptococcus pneumoniae caused a more profound pathogenicity than a mutant lacking its two sialidase genes.
These findings motivated Chen et al. 2 to assess the potential of sialidase inhibitors as a way to preserve the CD24/SiglecG/10 inhibitory circuit and moderate the effects of sialidase. Two sialidase inhibitors, 2,3-dehydro-2-deoxy-N-acetylneuraminic acid and 2,3-dehydro-2-deoxy-N-glycolylneuraminic acid, protected wild-type mice, but not Cd24 −/− or siglecg −/− mice, from experimental sepsis by cecal ligation and puncture. These results suggest that sialidase inhibitors might reduce the virulence and morbidity of sepsis involving bacterial pathogens that produce sialidases, such as Streptococcus pneumoniae, or polybacterial infections such as those produced from punctured intestine.
Siglec is not the first glycan receptor linked to sepsis caused by S. pneumoniae. Platelets are especially susceptible to loss of sialic acid by sialidase, resulting in clearance of the desialylated platelets by the asialo-glycoprotein receptor (ASGR) of liver hepatocytes 10 . ASGR-null mice exhibit more profound mortality as a result of increased levels of desialylated platelets and increased coagulopathy. In contrast to the results of Chen et al. 2 , Grewal et al. 10 found that a sialidase-deficient strain of S. pneumoniae produced increased mortality in wild-type mice. The apparently contradictory results may reflect the different levels of sialidase that affect the activities of two different receptor systems-one that clears desialylated platelets and reduces coagulation, and the other that is required for dampening the inflammatory response but is destroyed by sialidase.
Sialidase inhibitors are not new to the pharmaceutical industry. The influenza virus medicines Tamiflu and Relenza inhibit the influenza virus sialidase, which is required for spreading of the virus from infected cells. The results of The development of cotton fibers involves four partially overlapping stages [2] [3] [4] (Fig. 1) . Whereas lint fibers are long and can be spun into yarn, shorter fuzz fibers have no value for the textile industry. For upland cotton (Gossypium hirsutum L.), the epidermal cells that give rise to lint fibers appear before or on the day of anthesis (0 days post anthesis, DPA), and cells that initiate after approximately +4 or +5 DPA become fuzz fibers. Each cotton fiber is a single-celled seed trichome or hair, Cotton fiber is the largest renewable source of textile materials, with a global annual consumption of ~27 million metric tons worth ~$500 billion. Biotech has succeeded in raising cotton yields through the introduction of herbicide and insecticide transgenes, but improving the quality of cotton itself has not been possible without a penalty in fiber yield or seed size or number. In this issue, Zhang et al. 1 simultaneously improve the yield and quality of cotton fiber. The key to their success
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Increasing auxin levels at the right time and place during ovule and fiber development improves the yield and quality of cotton fibers. 
